Inflammatory Polymorphisms (IL-6 rs1800796, IL-10 rs1800896, TNF-α rs1800629, and IFITM3 rs12252) Are Not Associated with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors.

Publication date: Feb 09, 2024

The aim of this study was to identify the association between four selected inflammatory polymorphisms with the development of long-term post-COVID symptoms in subjects who had been hospitalized due to SARS-CoV-2 infection during the first wave of the pandemic. These polymorphisms were selected as they are associated with severe COVID-19 disease and cytokine storm, so they could be important to prognoses post-COVID. A total of 408 (48. 5% female, age: 58. 5 +/- 14. 0 years) previously hospitalized COVID-19 survivors participated. The three potential genotypes of the following four single-nucleotide polymorphisms, IL-6 rs1800796, IL-10 rs1800896, TNF-α rs1800629, and IFITM3 rs12252, were obtained from non-stimulated saliva samples of the participants. The participants were asked to self-report the presence of any post-COVID symptoms (defined as symptoms that had started no later than one month after SARS-CoV-2 acute infection) and whether the symptoms persisted at the time of the study. At the time of the study (mean: 15. 6, SD: 5. 6 months after discharge), 89. 4% of patients reported at least one post-COVID symptom (mean number of symptoms: 3. 0; SD: 1. 7). Fatigue (69. 3%), pain (40. 9%), and memory loss (27. 2%) were the most prevalent post-COVID symptoms in the total sample. Overall, no differences in the post-COVID symptoms depending on the IL-6 rs1800796, IL-10 rs1800896, TNF-α rs1800629, and IFITM3 rs12252 genotypes were seen. The four SNPs assessed, albeit having been previously associated with inflammation and COVID-19 severity, did not cause a predisposition to the development of post-COVID symptoms in the previously hospitalized COVID-19 survivors.

Open Access PDF

Concepts Keywords
Covid Adult
Pandemic Aged
Rs1800629 COVID-19
Survivors Female
genotypes
Humans
IFITM3
IFITM3 protein, human
IL-10
Interleukin-10
Interleukin-10
Interleukin-6
Interleukin-6
Male
Membrane Proteins
Membrane Proteins
Middle Aged
Polymorphism, Single Nucleotide
post-COVID
RNA-Binding Proteins
RNA-Binding Proteins
SARS-CoV-2
single-nucleotide polymorphism, IL-6
TNF-α
Tumor Necrosis Factor-alpha
Tumor Necrosis Factor-alpha

Semantics

Type Source Name
drug DRUGBANK Interleukin-10
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease MESH cytokine storm
disease VO report
disease IDO acute infection
disease VO time
disease IDO symptom
disease MESH inflammation
drug DRUGBANK Coenzyme M
drug DRUGBANK Angiotensin II
drug DRUGBANK Serine
disease IDO virulence
disease MESH long COVID
disease VO organization
disease IDO history
disease MESH infection
disease MESH cognitive dysfunction
disease IDO immune response
disease IDO assay
drug DRUGBANK Tromethamine
drug DRUGBANK Edetic Acid
disease MESH hair loss
disease VO ANOVA
disease VO age
disease MESH morbidities
disease MESH Hypertension
disease MESH Obesity
disease MESH Asthma
pathway KEGG Asthma
disease MESH Cardiovascular Diseases
disease MESH Gastrointestinal Disorders
disease VO vaccinated
disease VO vaccination
disease MESH autoimmunity
disease MESH latent infections
disease VO population
disease MESH coronavirus infection
disease IDO susceptibility
disease MESH Syndrome
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH sequelae
disease VO vaccine
drug DRUGBANK Troleandomycin
disease IDO host

Original Article

(Visited 1 times, 1 visits today)